Stroke due to basilar artery occlusion has a high mortality and morbidity. Intra-arterial thrombolysis has been reported to improve survival and outcome status. Our aim was to assess the safety and efficacy of intra-arterial urokinase in a consecutive series of patients with clinically severe brainstem ischaemic stroke and major vertebrobasilar vessel occlusion. Incremental doses of urokinase were administered until clot lysis was achieved, or until a limit of 1,000,000 U. Patients were then anticoagulated with heparin and warfarin, and 6-month functional status was measured by the Barthel index. Sixteen patients, aged 22–73 (median 60), were treated 5–31 (median 15) h following symptom onset. Thirteen of the 16 patients (82%) had initial complete or partial recanalisation. Complete occlusion of the basilar artery was present in 13, and recanalisation was achieved in 10 of these (77%), although 2 re-occluded. Four of 5 patients with persistent occlusion died, compared with only 1 death in 8 patients with sustained recanalisation (p = 0.02, Fisher''s exact test, one-tailed). Intra-arterial urokinase can recanalise basilar artery occlusion, with significant reduction in mortality at 6 months. A prospective randomised, controlled trial is necessary to confirm the benefit of this therapy.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.